NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents

Phase 1

Completed

Conditions: Influenza

Interventions: Biological: Seasonal Influenza DNA vaccine
Biological: TIV

First Posted Date: 2012-06-01

Last Posted Date: 2018-12-06

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 75

Registration Number: NCT01609998

Locations: 🇺🇸
Saint Louis University - Doisy Research Center, Saint Louis, Missouri, United States
🇺🇸
Emory Children's Center, Atlanta, Georgia, United States
🇺🇸
The Gamble Program for Clinical Studies, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

and more 2 locations

The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"

Phase 2

Completed

Conditions: Urinary Tract Infection

Interventions: Other: Placebo
Drug: Cefixime
Drug: Cephalexin
Drug: Trimethoprim/Sulfamethoxazole

First Posted Date: 2012-05-10

Last Posted Date: 2020-08-06

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 717

Registration Number: NCT01595529

Locations: 🇺🇸
Children's Hospital of Pittsburgh of UPMC - General Academic Pediatric, Pittsburgh, Pennsylvania, United States

Volunteer Screening for Vaccine and Antivirals Clinical Trials

Completed

Conditions: Normal Physiology

First Posted Date: 2012-05-08

Last Posted Date: 2021-08-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 359

Registration Number: NCT01593709

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis

Phase 4

Completed

Conditions: Loiasis

Interventions: Drug: Ivermectin
Drug: Diethylcarbamazine

First Posted Date: 2012-05-08

Last Posted Date: 2016-11-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 155

Registration Number: NCT01593722

Locations: 🇨🇲
Filariasis and other Tropical Diseases Research Center, Yaounde, Cameroon

Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73

Phase 1

Completed

Conditions: Staphylococcal Infection

Interventions: Drug: XF-73 in 2% Klucel gel
Other: Placebo
Drug: XF-73 in 4% Klucel gel

First Posted Date: 2012-05-07

Last Posted Date: 2016-09-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 48

Registration Number: NCT01592214

Locations: 🇺🇸
Anaheim Clinical Trials - Phase I Clinical Pharmacology Unit, Anaheim, California, United States
🇺🇸
Case Western Reserve University - Case Medical Center - Infectious Disease & HIV Medicine, Cleveland, Ohio, United States

Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: HIV-MAG vaccine
Biological: Placebo
Device: Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device
Biological: IL-12 pDNA adjuvant
Biological: VSV HIV gag vaccine

First Posted Date: 2012-04-17

Last Posted Date: 2021-10-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 100

Registration Number: NCT01578889

Locations: 🇺🇸
Columbia P&S CRS, New York, New York, United States
🇺🇸
New York Blood Center CRS, New York, New York, United States
🇺🇸
University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester, New York, United States

and more 2 locations

Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant

Phase 1

Completed

Conditions: Influenza

Interventions: Biological: H5N1 vaccine plus AS03 adjuvant
Biological: H5N1 vaccine without adjuvant

First Posted Date: 2012-04-16

Last Posted Date: 2019-02-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 43

Registration Number: NCT01578317

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single Dose or in Divided Doses to Healthy Adults

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Drug: Rifapentine (RPT)

First Posted Date: 2012-04-10

Last Posted Date: 2021-11-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 44

Registration Number: NCT01574638

Locations: 🇺🇸
UCSD Antiviral Research Center CRS, San Diego, California, United States
🇺🇸
Chapel Hill CRS, Chapel Hill, North Carolina, United States
🇺🇸
Johns Hopkins University CRS, Baltimore, Maryland, United States

and more 1 locations

H5N1 Vaccination With and Without AS03: Systems Biology Analysis

Phase 1

Completed

Conditions: Influenza

Interventions: Drug: ASO3 Adjuvant
Biological: Influenza A/H5N1 Vaccine

First Posted Date: 2012-04-09

Last Posted Date: 2019-10-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 20

Registration Number: NCT01573312

Locations: 🇺🇸
Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center, Nashville, Tennessee, United States

Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: GEO-D03 DNA vaccine
Biological: Placebo for GEO-D03 DNA
Biological: MVA/HIV62B (MVA62B) vaccine

First Posted Date: 2012-04-05

Last Posted Date: 2021-10-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 48

Registration Number: NCT01571960

Locations: 🇺🇸
Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston, Massachusetts, United States
🇺🇸
Bridge HIV CRS, San Francisco, California, United States
🇺🇸
University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester, New York, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy